SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    New Hampshire To Allow Visiting Patients From Other States & Canada To Pick Up Prescriptions

    By

    New Hampshire has passed new legislation which will enable medical cannabis patients from other states and Canada to ‘purchase therapeutic cannabis’.

    The New Hampshire Department of Health and Human Services announced yesterday (June 28) that the state’s ‘alternative treatment centres’, will now be able to issue prescriptions to tourists.

    Patients visiting from other states will be required to show their cannabis ID card and matching photo identification, and can only purchase up to 2 ounces three times a year.

    READ MORE: New Committee Will Work to Federally Legalise Cannabis

    “If the out-of-state patient has a documented qualifying medical condition that is on the list of conditions approved by New Hampshire, those visiting patients may purchase cannabis at New Hampshire ATCs at the same frequency as New Hampshire qualifying patients,” the agency said.

    The medical conditions currently approved by New Hampshire include autism spectrum disorder, moderate or severe post traumatic stress disorder, moderate or severe chronic pain, and opioid use disorder.

    While New Hampshire was one of the earliest adopters of medical cannabis in the US, passing a law to legalise it in 2013, it remains the only state in New England that hasn’t legalised adult-use.

    Ben Stevens

    Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free